American Association for Cancer Research (AACR) shared a post on X:
“The KRAS inhibitor zoldonrasib showed effective and durable responses in patients with previously treated G12D-mutated non-small cell lung cancer, according to updated results from a phase I clinical trial reported at AACR26 by Jonathan W. Riess.”
Other Articles Featuring AACR on OncoDaily.